UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.856

Sortiert nach

Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

PloS one, 2015-10, Vol.10 (10), p.e0139440-e0139440

2015

Volltextzugriff (PDF)

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

The New England journal of medicine, 2017-07, Vol.377 (4), p.352-360

2017

Volltextzugriff (PDF)

The European Bioinformatics Institute in 2016: Data growth and integration

Nucleic acids research, 2016-01, Vol.44 (D1), p.D20

2016

Volltextzugriff (PDF)

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

The lancet oncology, 2018-02, Vol.19 (2), p.194-206

2018

Volltextzugriff (PDF)

An Islamic framework for animal ethics: Widening the conversation to include Islamic ethical vegetarianism

Critical research on religion, 2023-12, Vol.11 (3), p.263-280

2023

Volltextzugriff (PDF)

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

The New England journal of medicine, 2017-07, Vol.377 (4), p.352-360

2017

Volltextzugriff (PDF)

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

European urology, 2017-04, Vol.71 (4), p.656-664

2017

Volltextzugriff (PDF)

Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease

Cancer, 2017-09, Vol.123 (18), p.3591-3601

2017

Volltextzugriff (PDF)

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

European urology, 2016-09, Vol.70 (3), p.438-444

2016

Volltextzugriff (PDF)

Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

European urology, 2017-07, Vol.72 (1), p.10-13

2017

Volltextzugriff (PDF)

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data

Cancer medicine (Malden, MA), 2016-02, Vol.5 (2), p.182-191

2016

Volltextzugriff (PDF)

Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate

The Journal of community and supportive oncology, 2016-04, Vol.14 (4), p.148-154

2016

Volltextzugriff (PDF)

Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database

Clinical genitourinary cancer, 2017-04, Vol.15 (2), p.273-279.e1

2017

Volltextzugriff (PDF)

A LAST WORD

Phi Kappa Phi forum, 2021-07, Vol.101 (2), p.0_2-0_2

Todd, Mary

2021

Volltextzugriff (PDF)